Literature DB >> 21877216

Neurologic and psychiatric manifestations of celiac disease and gluten sensitivity.

Jessica R Jackson1, William W Eaton, Nicola G Cascella, Alessio Fasano, Deanna L Kelly.   

Abstract

Celiac Disease (CD) is an immune-mediated disease dependent on gluten (a protein present in wheat, rye or barley) that occurs in about 1% of the population and is generally characterized by gastrointestinal complaints. More recently the understanding and knowledge of gluten sensitivity (GS), has emerged as an illness distinct from celiac disease with an estimated prevalence 6 times that of CD. Gluten sensitive people do not have villous atrophy or antibodies that are present in celiac disease, but rather they can test positive for antibodies to gliadin. Both CD and GS may present with a variety of neurologic and psychiatric co-morbidities, however, extraintestinal symptoms may be the prime presentation in those with GS. However, gluten sensitivity remains undertreated and underrecognized as a contributing factor to psychiatric and neurologic manifestations. This review focuses on neurologic and psychiatric manifestations implicated with gluten sensitivity, reviews the emergence of gluten sensitivity distinct from celiac disease, and summarizes the potential mechanisms related to this immune reaction.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21877216      PMCID: PMC3641836          DOI: 10.1007/s11126-011-9186-y

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN: 0033-2720


  79 in total

1.  Immune cross-reactivity in celiac disease: anti-gliadin antibodies bind to neuronal synapsin I.

Authors:  Armin Alaedini; Haruka Okamoto; Chiara Briani; Kurt Wollenberg; Holly A Shill; Khalafalla O Bushara; Howard W Sander; Peter H R Green; Mark Hallett; Norman Latov
Journal:  J Immunol       Date:  2007-05-15       Impact factor: 5.422

2.  Markers of gluten sensitivity and celiac disease in recent-onset psychosis and multi-episode schizophrenia.

Authors:  Faith Dickerson; Cassie Stallings; Andrea Origoni; Crystal Vaughan; Sunil Khushalani; Flora Leister; Shuojia Yang; Bogdana Krivogorsky; Armin Alaedini; Robert Yolken
Journal:  Biol Psychiatry       Date:  2010-05-14       Impact factor: 13.382

3.  Monosialoganglioside (GM1) immunofluorescence in rat spinal roots studied with a monoclonal antibody.

Authors:  M Molander; C H Berthold; H Persson; K Andersson; P Fredman
Journal:  J Neurocytol       Date:  1997-02

4.  Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives.

Authors:  Laura de Magistris; Valeria Familiari; Antonio Pascotto; Anna Sapone; Alessandro Frolli; Patrizia Iardino; Maria Carteni; Mario De Rosa; Ruggiero Francavilla; Gabriele Riegler; Roberto Militerni; Carmela Bravaccio
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-10       Impact factor: 2.839

5.  Improvement in central monoamine metabolism in adult coeliac patients starting a gluten-free diet.

Authors:  C Hallert; G Sedvall
Journal:  Psychol Med       Date:  1983-05       Impact factor: 7.723

6.  A preliminary investigation of ADHD symptoms in persons with celiac disease.

Authors:  Helmut Niederhofer; Klaus Pittschieler
Journal:  J Atten Disord       Date:  2006-11       Impact factor: 3.256

7.  Autoantibodies in gluten ataxia recognize a novel neuronal transglutaminase.

Authors:  Marios Hadjivassiliou; Pascale Aeschlimann; Alexander Strigun; David S Sanders; Nicola Woodroofe; Daniel Aeschlimann
Journal:  Ann Neurol       Date:  2008-09       Impact factor: 10.422

8.  Neurological disorders and adult coeliac disease.

Authors:  J S Morris; A B Ajdukiewicz; A E Read
Journal:  Gut       Date:  1970-07       Impact factor: 23.059

9.  Novel immune response to gluten in individuals with schizophrenia.

Authors:  Diana Samaroo; Faith Dickerson; Donald D Kasarda; Peter H R Green; Chiara Briani; Robert H Yolken; Armin Alaedini
Journal:  Schizophr Res       Date:  2009-09-11       Impact factor: 4.939

Review 10.  Progressive myoclonic ataxia associated with coeliac disease. The myoclonus is of cortical origin, but the pathology is in the cerebellum.

Authors:  K P Bhatia; P Brown; R Gregory; G G Lennox; H Manji; P D Thompson; D W Ellison; C D Marsden
Journal:  Brain       Date:  1995-10       Impact factor: 13.501

View more
  53 in total

1.  A gluten-free diet in people with schizophrenia and anti-tissue transglutaminase or anti-gliadin antibodies.

Authors:  Jessica Jackson; William Eaton; Nicola Cascella; Alessio Fasano; Dale Warfel; Stephanie Feldman; Charles Richardson; Gopal Vyas; Jared Linthicum; Debby Santora; Kimberly R Warren; William T Carpenter; Deanna L Kelly
Journal:  Schizophr Res       Date:  2012-07-07       Impact factor: 4.939

2.  Immunoglobulin G genotypes and the risk of schizophrenia.

Authors:  Janardan P Pandey; Aryan M Namboodiri; Robert C Elston
Journal:  Hum Genet       Date:  2016-07-08       Impact factor: 4.132

Review 3.  Anti-type 2 transglutaminase antibodies as modulators of type 2 transglutaminase functions: a possible pathological role in celiac disease.

Authors:  Stefania Martucciello; Gaetana Paolella; Carla Esposito; Marilena Lepretti; Ivana Caputo
Journal:  Cell Mol Life Sci       Date:  2018-08-22       Impact factor: 9.261

4.  Gluten sensitivity and relationship to psychiatric symptoms in people with schizophrenia.

Authors:  Jessica Jackson; William Eaton; Nicola Cascella; Alessio Fasano; Debby Santora; Kelli Sullivan; Stephanie Feldman; Heather Raley; Robert P McMahon; William T Carpenter; Haley Demyanovich; Deanna L Kelly
Journal:  Schizophr Res       Date:  2014-10-11       Impact factor: 4.939

5.  Clinically Significant Symptom Reduction in Children with Attention-Deficit/Hyperactivity Disorder Treated with Micronutrients: An Open-Label Reversal Design Study.

Authors:  Heather A Gordon; Julia J Rucklidge; Neville M Blampied; Jeanette M Johnstone
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-12       Impact factor: 2.576

6.  Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia.

Authors:  Emily G Severance; Kristin L Gressitt; Cassie R Stallings; Andrea E Origoni; Sunil Khushalani; F Markus Leweke; Faith B Dickerson; Robert H Yolken
Journal:  Schizophr Res       Date:  2013-06-06       Impact factor: 4.939

7.  Use of a Gluten-Free Diet in Schizophrenia: A Systematic Review.

Authors:  Anastasia Levinta; Ilya Mukovozov; Christopher Tsoutsoulas
Journal:  Adv Nutr       Date:  2018-11-01       Impact factor: 8.701

Review 8.  Broad-spectrum micronutrient treatment for attention-deficit/hyperactivity disorder: rationale and evidence to date.

Authors:  Julia J Rucklidge; Bonnie J Kaplan
Journal:  CNS Drugs       Date:  2014-09       Impact factor: 5.749

9.  Food-derived opioid peptides inhibit cysteine uptake with redox and epigenetic consequences.

Authors:  Malav S Trivedi; Jayni S Shah; Sara Al-Mughairy; Nathaniel W Hodgson; Benjamin Simms; Geert A Trooskens; Wim Van Criekinge; Richard C Deth
Journal:  J Nutr Biochem       Date:  2014-06-06       Impact factor: 6.048

Review 10.  Extraintestinal manifestations of coeliac disease.

Authors:  Daniel A Leffler; Peter H R Green; Alessio Fasano
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-08-11       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.